Thyroid function and life expectancy with and without noncommunicable diseases: A population-based study by Bano, A. (Arjola) et al.
RESEARCH ARTICLE
Thyroid function and life expectancy with and
without noncommunicable diseases:
A population-based study
Arjola BanoID1,2,3,4, Layal Chaker1,2, Francesco U. S. Mattace-Raso5, Natalie Terzikhan2,
Maryam Kavousi2, M. Arfan IkramID2, Robin P. Peeters1,2*, Oscar H. Franco2,3
1 Department of Internal Medicine and Academic Center for Thyroid Diseases, Erasmus Medical Center,
Rotterdam, the Netherlands, 2 Department of Epidemiology, Erasmus Medical Center, Rotterdam, the
Netherlands, 3 Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland,
4 Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland,
5 Section of Geriatric Medicine, Erasmus Medical Center, Rotterdam, the Netherlands
* r.peeters@erasmusmc.nl
Abstract
Background
Variations in thyroid function within reference ranges are associated with increased risk of
diseases and death. However, the impact of thyroid function on life expectancy (LE) with
and without noncommunicable diseases (NCDs) remains unknown. We therefore aimed to
investigate the association of thyroid function with total LE and LE with and without NCD
among euthyroid individuals.
Methods and findings
The study was embedded in the Rotterdam Study, a prospective population-based study
carried out in the Netherlands. In total, 7,644 participants without known thyroid disease and
with thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels within reference
ranges were eligible. NCDs were defined as presence of cardiovascular disease, diabetes
mellitus type 2, or cancer. We used the demographic tool of multistate life tables to calculate
LE estimates at the age of 50 years, using prevalence, incidence rates, and hazard ratios for
three transitions (healthy to NCD, healthy to death, and NCD to death). The total LE and LE
with and without NCD among TSH and FT4 tertiles were calculated separately in men and
women. Analyses were adjusted for sociodemographic and cardiovascular risk factors. The
mean (standard deviation) age of the participants was 64.5 (9.7) years, and 52.3% were
women. Over a median follow-up of 8 years (interquartile range 2.7–9.9 years), 1,396 inci-
dent NCD events and 1,422 deaths occurred. Compared with those in the lowest TSH tertile,
men and women in the highest TSH tertile were expected to live 1.5 years (95% confidence
interval [CI] 0.8–2.3, p < 0.001) and 1.5 years (CI 0.8–2.2, p < 0.001) longer, respectively, of
which 1.4 years (CI 0.5–2.3, p = 0.002) and 1.3 years (CI 0.3–2.1, p = 0.004) with NCD.
Compared with those in the lowest FT4 tertile, the difference in LE for men and women in the
highest FT4 tertile was −3.7 years (CI −5.1 to −2.2, p < 0.001) and −3.3 years (CI −4.7 to
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−1.9, p < 0.001), respectively, of which −1.8 years (CI −3.1 to −0.7, p = 0.003) and −2.0
years (CI −3.4 to −0.7, p = 0.003) without NCD. A limitation of the study is the observational
design. Thus, the possibility of residual confounding cannot be entirely ruled out.
Conclusions
In this study, we found that people with low–normal thyroid function (i.e., highest tertile of
TSH and lowest tertile of FT4 reference ranges) are expected to live more years with and
without NCD than those with high–normal thyroid function (i.e., lowest tertile of TSH and
highest tertile of FT4 reference ranges). These findings provide support for a re-evaluation
of the current reference ranges of thyroid function.
Author summary
Why was this study done?
• Thyroid dysfunction is an important public health problem that is associated with an
increased risk of noncommunicable diseases (NCDs), such as cardiovascular diseases,
diabetes, and cancer. The diagnosis and treatment of thyroid dysfunction is based on
thyrotropin and free thyroxine measurements.
• Accumulating evidence has suggested that the clinical consequences of thyroid dysfunction
are extended even within the reference ranges of thyrotropin and free thyroxine levels.
• However, the impact of thyroid function on life expectancy with and without NCD
remains unknown.
What did the researchers do and find?
• We performed a large prospective population-based cohort study within the framework
of the Rotterdam Study.
• We investigated the association of thyroid function with life expectancy with and with-
out NCD among euthyroid individuals.
• We found that individuals with low–normal thyroid function live up to 3.7 years longer
overall, of which up to 1.9 years longer with NCD, than individuals with high–normal
thyroid function.
What do these findings mean?
• Our study provides novel insights about the qualitative and quantitative impact of thy-
roid function on life expectancy.
• Our findings provide support for a re-evaluation of the reference ranges of thyroid func-
tion in middle-aged and older adults. This can have further implications on the diagno-
sis and treatment of thyroid disease.
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Introduction
Noncommunicable diseases (NCDs) pose a global health threat, inflicting high disability rates
and a huge economic burden [1,2]. According to the World Health Organization, NCDs
account for approximately 41 million deaths worldwide each year [2,3]. Global preventive
strategies can be beneficial for cardiovascular disease (CVD), diabetes, cancer, and chronic
kidney disease (CKD), which account for large proportions of deaths and a large number of
years lived with disability [4]. Among other factors, clinical and subclinical thyroid dysfunc-
tion have been associated with CVD, diabetes, cancer, and NCD mortality [5–9].
Thyroid dysfunction is defined based on the circulating levels of thyroid-stimulating hor-
mone (TSH) and free thyroxine (FT4) [10]. The secretion of these hormones is regulated by
the hypothalamus–pituitary–thyroid axis via a negative-feedback mechanism [10]. The refer-
ence ranges of TSH and FT4 levels are crucial for the diagnosis and treatment of thyroid dis-
ease. However, over the past years, there has been an ongoing debate on whether the reference
ranges of TSH and FT4 levels should be re-evaluated [11,12]. The debate has arisen from stud-
ies indicating that not only thyroid disease but also variations in thyroid function within the
reference ranges can contribute to the occurrence of chronic conditions and deaths [11,13–
15]. Prospective investigations in euthyroid individuals have suggested that high–normal thy-
roid function increases the risk of CVD, cancer, or CKD, whereas low–normal thyroid func-
tion has been associated with an increased risk of chronic metabolic diseases, such as diabetes
[11,14–19]. Based on this evidence, it is challenging to determine the balance of overall benefits
and risks for specific cutoffs of TSH and FT4 levels within the reference ranges [20,21]. In
order to capture the pleiotropic effects of thyroid hormones, there is a need for utilizing com-
posite measurements that integrate multiple aspects of health and disease rather than focusing
on one adverse outcome alone. A recent study utilizing life expectancy (LE) measurements
showed that middle-aged and older adults with low–normal thyroid function have a longer
total LE and a longer LE without CVD than those with high–normal thyroid function [22].
Still, it remains unclear whether the differences in LE without CVD reflect healthy years or
years lived with other chronic diseases. To address this, multidimensional measures such as LE
with and without NCD can provide useful information on the qualitative and quantitative
impact of thyroid function on general health.
In a large prospective population-based cohort study, we investigated (1) the association of
thyroid function within the reference range with the risk of incident NCD and (2) whether
there are differences in the number of years lived with and without NCD, within the reference
range of thyroid function. NCDs were defined as the presence of CVD, diabetes, or cancer,
which have been highlighted as a global threat by the United Nations and have been prospec-
tively associated with thyroid function [13,14,22,23]. CKD was added to the definition of NCD
in a secondary analysis.
Methods
Study population
This study was embedded within the Rotterdam Study, a prospective population-based cohort
study. The Rotterdam Study investigates the determinants, occurrence, and progression of
chronic diseases in middle-aged and older adults from the Netherlands (overall response rate
of the study, 72%). The objectives and design have been described in detail previously [24].
The study was initiated in 1989, including 7,983 participants aged 55 years or older. In 2000,
the study was extended with a second cohort of 3,011 individuals. In 2006, a third cohort of
3,932 individuals aged 45 years or older was added. Study participants underwent extensive
Thyroid function and life expectancy with and without disease
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follow-up medical examinations every 3–5 years. Baseline measurements for our study were
performed during the third visit of the first cohort (RS-I.3, 1997–1999, n = 4,797) and the first
visits of the second (RS-II.1, 2000–2001, n = 3,011) and third (RS-III.1, 2006–2008, n = 3,932)
cohorts of the Rotterdam Study. The original cohort during these three visits included a total
of 11,740 participants, of which 10,050 had available blood measurements. Thyroid function
measurements were performed in a random sample of 9,702 participants. Of these, we
excluded 836 participants with past thyroid disease or who were taking thyroid medications,
182 participants without complete information on prevalent or incident NCD, and 1,040 par-
ticipants with TSH or FT4 outside the normal reference ranges. The remaining 7,644 partici-
pants with data available on NCD, without known thyroid disease, and with TSH and FT4
levels within the reference ranges were eligible. The Rotterdam Study was approved by the
Medical Ethics Committee of Erasmus University and by the Ministry of Health, Welfare and
Sport of the Netherlands, implementing the Population Study Act Rotterdam Study. In accor-
dance with the Declaration of Helsinki, all participants provided written informed consent.
This study is reported per the Strengthening the Reporting of Observational Studies in Epide-
miology (STROBE) guideline (S1 STROBE Checklist).
Assessment of thyroid parameters
Thyroid function was assessed at baseline (RS-I.3 1997–1999; RS-II.1 2000–2001, and RS-III.1
2006–2008) using the same method, assay, and reference ranges. Measurements of TSH and
FT4 were performed in baseline serum samples stored at −80˚C using the Roche electrochemi-
luminescence immunoassay (ECLIA). The reference ranges of TSH (0.4–4 mIU/L) and FT4
(0.86–1.94 ng/dL, alternatively 11–25 pmol/L) were determined based on national guidelines
and our previous studies [18,19]. Participants and family physicians were not informed about
the results of thyroid function measurements. The study investigators assessing the outcomes
of interest were blinded to the thyroid status of participants. Thyroid peroxidase antibodies
(TPOAbs) were assessed with the ECLIA for TPOAbs (Roche Diagnostics International, Rotk-
reuz, Switzerland). TPOAbs > 35 kU/mL were considered positive, as recommended by the
assay manufacturer.
NCD, mortality, and additional measurements
Outcome measures were incident nonfatal NCD, mortality among those with NCD, and over-
all mortality. NCDs were defined as presence of at least one disease out of CVD, diabetes melli-
tus type 2, or cancer. All events were independently assessed by two research physicians and
further validated by a medical specialist. Information on mortality was obtained from munici-
pality records, general practitioners, and reports of medical specialists [24,25]. CVD was
defined as presence of coronary heart disease (CHD), stroke, or heart failure. CHD was
defined as coronary revascularization, myocardial infarction, or fatal CHD [25]. Based on the
World Health Organization criteria, stroke was defined as a syndrome of rapidly developing
symptoms with an apparent vascular cause of focal or global cerebral dysfunction lasting 24
hours or longer or leading to death [26]. Based on the European Society of Cardiology criteria,
heart failure was defined as the presence of typical symptoms and signs—breathlessness at rest
or during exertion, ankle edema, and pulmonary crepitations—confirmed by the objective evi-
dence of cardiac dysfunction (i.e., chest X-ray, echocardiography) or a positive response to the
initiated treatment [27]. Prevalent CVD was assessed at baseline through interview and medi-
cal records. After enrollment, participants were monitored for incident CVD through linkage
of the study database with files from general practitioners and hospital records. Diabetes melli-
tus was defined as a fasting serum glucose level� 7 mmol/L, a nonfasting plasma glucose
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level� 11.1 mmol/L (when fasting samples were absent), or the use of blood glucose–lowering
medications [28]. Cases of type 2 diabetes were ascertained at baseline and during follow-up
through general practitioners, hospital discharge letters, and serum glucose measurements
from the Rotterdam Study visits. Information regarding the use of blood glucose–lowering
medications was derived from both structured home interviews and linkage to pharmacy rec-
ords [28]. Cancer events were classified according to the International Classification of Diseases
(ICD) 10th Edition [29]. Cases of cancer were determined through general practitioners and
hospital discharge letters and by linkage with a nationwide registry of histopathology and cyto-
pathology in the Netherlands, Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief
(PALGA) [29]. All types of cancer events were confirmed by pathology records. All cancer
events were combined. The most common cancers in the Rotterdam Study are breast cancer,
prostate cancer, pancreatic cancer, lung cancer, and colorectal cancer.
Additional measurements
The baseline home interview provided information on medical history, medication use,
tobacco smoking, alcohol consumption, education level, and marital status [24]. Smoking hab-
its were categorized as current, former, and never smoking. Education level was categorized as
elementary, lower secondary, higher secondary, and tertiary. Marital status was categorized as
single, married, widowed, and divorced/separated. Lipid levels were measured by an auto-
mated enzymatic procedure (Mannheim system). Anthropometric measurements were per-
formed in the research center by trained medical staff. Body mass index was calculated as
weight in kilograms divided by height in meters squared. Blood pressure was measured in the
sitting position on the right arm and calculated as the mean of two measurements using a ran-
dom-zero sphygmomanometer. In order to perform sensitivity analyses, we also evaluated
CKD and chronic obstructive pulmonary disease (COPD). CKD was defined as estimated glo-
merular filtration rate (eGFR) < 60 ml/min per 1.73 m2. eGFR was calculated at baseline and
follow-up visits according to the CDK epidemiology collaboration equation [30]. Patients with
incident CKD were defined as individuals free of CKD at baseline (eGFR> 60 ml/min per
1.73 m2) who had a decline in eGFR to<60 ml/min per 1.73 m2 between the two periodic
examinations [31]. To estimate the censoring date of the cases, we assumed a linear decrease in
eGFR. The date that each case had passed the eGFR threshold of 60 ml/min per 1.73 m2 was
taken as the censoring date, and it was used to calculate the follow-up time for incident cases.
For participants who remained free from CKD, the time spent between the two examinations
was used as the follow-up time. COPD was diagnosed based on an obstructive prebronchodila-
tor spirometry (FEV1/FVC < 0.70) according to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines [32]. The incident date of COPD was defined as the date of
the first obstructive lung function examination, the date of COPD diagnosis in the medical rec-
ords, or the date of the first prescription of COPD medications, whichever came first.
Statistical analyses
An outline of the analysis plan of this study is provided in S1 Text. We did not publish or pre-
register the analysis plan. The multistate life table is a demographic tool that can estimate the
total LE and disease-specific life expectancies using information from people at different ages
moving between different health states (e.g., healthy, diseased, dead) [33]. We used multistate
lifetables to calculate estimates of total LE and LE with and without NCD among tertiles of
TSH and FT4 [34]. Multistate life tables combined information from participants in three pos-
sible health states—namely, “free of NCD,” “NCD,” and “death.” Possible transitions of partici-
pants were (1) from free of NCD to NCD (incident NCD), (2) from free of NCD to death
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(mortality among those without NCD), and (3) from NCD to death (mortality among those
with NCD). Backflows were not allowed, and only the first event into a state was considered
[33]. The analyses were performed separately for TSH and FT4 tertiles. Because of the known
gender differences in LE, analyses were performed separately among men and women. To cal-
culate LE, we followed a similar approach to previous studies [34,35]. We first calculated the
prevalence of TSH tertiles among participants with and without NCD, categorized in 10-year
age groups. In each transition, we calculated age-specific incidence rates. Next, we applied
Poisson regression with Gompertz distribution to compute hazard ratios (HRs) of the associa-
tion between TSH tertiles and incident NCD or mortality, adjusting for potential confounders.
Differences in LE were evaluated using the lowest TSH tertile as a reference. The 95% confi-
dence intervals (CIs) of LE estimates were calculated using the Monte Carlo method with
10,000 bootstrap simulations [36]. We repeated the analyses for the FT4 tertiles. Differences in
LE were evaluated using the lowest FT4 tertile as a reference. Confounders were selected based
on biological plausibility and previous literature. Model 1 was adjusted for age, sex, and cohort.
Model 2 was adjusted for age, sex, cohort, smoking, alcohol intake, education level, marital sta-
tus, body mass index, systolic blood pressure, total cholesterol, triglycerides, use of antihyper-
tensive medications, and use of lipid-lowering medications. Multiple imputations were
performed in case of missing covariates (<5% for all covariates). Statistical analyses were con-
ducted using IBM SPSS version 21 (IBM), STATA version 13 for Windows (StataCorp), and
@RISK software (Palisade).
Sensitivity analyses
(1) To account for potential reverse causation, we excluded NCD events or deaths that
occurred during the first 2 years of follow-up. (2) We excluded participants using thyroid func-
tion–altering medications, such as amiodarone or corticosteroids. (3) To detect a potential
influence of follow-up duration on our results, we performed the analyses restricting the length
of follow-up to 8 years (median follow-up time). (4) CKD was defined by eGFR, measured up
to two times within our cohort, and was added to the definition of NCD in a sensitivity analy-
sis. (5) COPD was not included in the primary outcome of NCD, because of the lack of evi-
dence of a pathophysiological association between thyroid function and incident COPD.
However, we performed a sensitivity analysis adding COPD to the definition of NCD. (6) We
assessed the differences in LE with and without CVD, diabetes, and cancer, separately, among
the TSH and FT4 tertiles. (7) We calculated unadjusted HRs for incident NCD and death
among TSH and FT4 tertiles. (8) To account for the potential role of thyroid autoimmunity,
we additionally adjusted our analyses for TPOAb positivity. Furthermore, we investigated the
association of TPOAb positivity with incident NCD and NCD mortality among those with
and without disease.
Results
A total of 7,644 participants with complete data available on NCD, without known thyroid dis-
ease, and with TSH and FT4 levels within the reference ranges were considered eligible. Base-
line characteristics of eligible participants are presented in Table 1. The mean (standard
deviation) age of participants was 64.5 (9.7) years, and 52.3% were women. Over a median fol-
low-up time of 8 years (interquartile range 2.7–9.9 years), 1,396 incident NCD events and
1,422 deaths occurred. Both models yielded similar estimates; therefore, we further report the
results of the most adjusted model (model 2), which accounted for age, sex, cohort, smoking,
alcohol intake, education level, marital status, body mass index, systolic blood pressure, total
Thyroid function and life expectancy with and without disease
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cholesterol, triglycerides, use of antihypertensive medications, and use of lipid-lowering
medications.
Association of thyroid function within the reference range with the risk of
NCD and death
The association of TSH tertiles with the risk of incident NCD was not statistically significant
(Table 2). Among participants without NCD, the highest TSH tertile was associated with a
lower risk of mortality compared with the lowest TSH tertile (HR, 0.67; 95% CI 0.54–0.83; p-
value < 0.001) (Table 2). Among participants with NCD, the highest TSH tertile had a border-
line statistically significant association with a lower risk of mortality than the lowest TSH tertile
(HR, 0.88; 95% CI 0.75–1.03; p-value = 0.1) (Table 2).
The highest FT4 tertile was associated with a 1.17-times-higher risk of incident NCD than
the lowest FT4 tertile (HR, 1.17; 95% CI 1.02–1.34; p-value = 0.02) (Table 2). The highest FT4
tertile was also associated with a 1.56-times-higher risk of mortality among participants with
NCD (HR, 1.56; 95% CI 1.32–1.85; p-value < 0.001) and a 1.44-times-higher risk of mortality
Table 1. Baseline characteristics of 7,644 participants.
Baseline characteristics Men Women
Number 3,647 3,997
Age, years 64.2 (9.2) 64.8 (10.1)
Smoking, n (%)
Current 897 (24.6) 810 (20.3)
Former 2,143 (58.8) 1,512 (37.8)
Never 607 (16.6) 1,675 (41.9)
Education, n (%)
Elementary 332 (9.1) 588 (14.7)
Lower secondary 1,041 (28.5) 2,012 (50.3)
Higher secondary 1,335 (36.6) 900 (22.5)
Tertiary 939 (25.7) 497 (12.4)
Marital status, n (%)
Single 115 (3.2) 244 (6.1)
Married 3,113 (85.4) 2,474 (61.9)
Widowed 222 (6.1) 870 (21.8)
Divorced/separated 197 (5.4) 409 (10.2)
BMI, kg/m2 27.0 (3.5) 27.3 (4.6)
Systolic blood pressure, mm Hg 141.0 (20.3) 137.8 (21.5)
Use of antihypertensive medications, n (%) 811 (22.2) 927 (23.2)
Total cholesterol, mmol/l 5.4 (0.9) 5.9 (0.9)
Triglycerides, mmol/l 1.6 (0.9) 1.5 (0.7)
Use of lipid-lowering medications, n (%) 662 (18.2) 576 (14.4)
TSH, mIU/L, median (IQR) 1.8 (1.2–2.4) 1.9 (1.3–2.6)
FT4, pmol/l 15.9 (2.0) 15.6 (1.9)
TPOAb positive, n (%) 187 (5.1) 457 (11.4)
Data are means (sd), unless otherwise specified. TPOAb > 35 kU/mL were considered positive, as recommended by
the assay manufacturer.
Abbreviations: BMI, body mass index; FT4, free thyroxine; IQR, interquartile range; sd, standard deviation; TPOAb,
thyroid peroxidase antibody; TSH, thyroid-stimulating hormone
https://doi.org/10.1371/journal.pmed.1002957.t001
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among participants without NCD (HR, 1.44; 95% CI 1.15–1.79; p-value = 0.001) (Table 2),
compared with the lowest FT4 tertile.
Results for TSH and FT4 analyses remained similar in the raw models, after excluding the
events that occurred during the first 2 years of follow-up, after excluding users of thyroid func-
tion–altering medications, and after additionally adjusting for TPOAb positivity (S1 Table, S2
Table, S3 Table). TPOAb positivity was not associated with the risk of incident NCD, mortality
among those without NCD, and mortality among those with NCD (HR, 1.20; 95% CI 0.99–
1.44; p-value 0.06; HR, 1.24; 95% CI 0.92–1.68, p-value = 0.2; HR, 0.97; 95% CI 0.76–1.25;
p-value = 0.8; respectively).
Association of thyroid function within the reference range with total LE
and LE with and without NCD
Total LE was higher in the middle than in the lowest TSH tertile and did not change substan-
tially from the middle to the highest TSH tertile (Fig 1). Compared with those in the lowest
TSH tertile, men in the highest TSH tertile were expected to live 1.5 years (95% CI 0.8–2.3;
p-value< 0.001) longer overall; of which 0.1 years (95% CI −0.8 to 1.2; p-value = 0.8) longer
without NCD and 1.4 years (95% CI 0.5–2.3; p-value = 0.002) longer with NCD (Table 3).
Compared with those in the lowest TSH tertile, women in the highest TSH tertile were
expected to live 1.5 years (95% CI 0.8–2.2; p-value < 0.001) longer overall; of which 0.2 years
(95% CI −0.8 to 1.3; p-value 0.7) longer without NCD, and 1.3 years (95% CI 0.3–2.1; p-value
0.004) longer with NCD (Table 3).
Total LE decreased progressively with increasing FT4 tertiles (Fig 1). Compared with those
in the lowest FT4 tertile, the difference in LE for men in the highest FT4 tertile was −3.7 years
(95% CI −5.1 to −2.2; p-value < 0.001) overall; of which −1.8 years (95% CI −3.1 to −0.7;
p-value 0.003) without NCD, and −1.9 years (95% CI −3.4 to −0.3; p-value 0.01) with NCD
(Table 3). Compared with those in the lowest FT4 tertile, the difference in LE for women in the
Table 2. HRs for incident NCD and death among TSH and FT4 tertiles.
TSH FT4
Transition Cases/PY TSH/FT4
tertiles
Model 1
HR (95% CI) (p-value)
Model 2
HR (95% CI) (p-value)
Model 1
HR (95% CI) (p-value)
Model 2
HR (95% CI) (p-value)
Incident NCD 1,396/
27,705
Tertile 1 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Tertile 2 0.98 (0.86–1.11) (0.7) 0.98 (0.86–1.12) (0.8) 1.16 (1.01–1.32) (0.02) 1.17 (1.02–1.33) (0.01)
Tertile 3 1.05 (0.92–1.19) (0.4) 1.05 (0.92–1.19) (0.4) 1.17 (1.02–1.33) (0.02) 1.17 (1.02–1.34) (0.02)
Mortality among those without
NCD
532/32,828 Tertile 1 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Tertile 2 0.68 (0.55–0.83)
(<0.001)
0.70 (0.56–0.85)
(<0.001)
1.21 (0.96–1.51) (0.09) 1.20 (0.95–1.50) (0.1)
Tertile 3 0.64 (0.52–0.79)
(<0.001)
0.67 (0.54–0.83)
(<0.001)
1.52 (1.22–1.88)
(<0.001)
1.44 (1.15–1.79)
(0.001)
Mortality among those with
NCD
890/18,456 Tertile 1 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Tertile 2 0.90 (0.77–1.06) (0.2) 0.91 (0.78–1.06) (0.2) 1.23 (1.03–1.47) (0.01) 1.24 (1.04–1.47) (0.01)
Tertile 3 0.84 (0.72–0.99) (0.04) 0.88 (0.75–1.03) (0.1) 1.59 (1.35–1.88)
(<0.001)
1.56 (1.32–1.85)
(<0.001)
NCDs include cardiovascular disease, diabetes mellitus, and cancer. Poisson regression with Gompertz distribution was used to compute HRs (and 95% CI) for the
association of TSH and FT4 tertiles with incident NCD and mortality. Model 1: age, sex, and cohort. Model 2: age, sex, cohort, smoking, alcohol intake, education level,
marital status, body mass index, systolic blood pressure, total cholesterol, triglycerides, use of antihypertensive medications, and use of lipid-lowering medications.
Abbreviations: CI, confidence interval; FT4, free thyroxine; HR, hazard ratio; NCD, noncommunicable disease; PY, person-year; TSH, thyroid-stimulating hormone
https://doi.org/10.1371/journal.pmed.1002957.t002
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highest FT4 tertile was −3.3 years (95% CI −4.7 to −1.9; p-value< 0.001) overall; of which −2.0
years (95% CI −3.4 to −0.7; p-value 0.003) without NCD and −1.3 years (95% CI −2.7 to 0.2; p-
value 0.07) with NCD (Table 3). Results remained similar over the length of follow-up of 8
years (S4 Table) or after including CKD in the definition of NCD (S5 Table) or after including
COPD in the definition of NCD (S6 Table). Compared with those in the lowest FT4 tertile,
men and women in the highest FT4 tertile were expected to live fewer years free of CVD, diabe-
tes, and cancer, respectively (S7 Table, S8 Table, S9 Table).
Fig 1. LE with and without NCD at age 50 years among TSH and FT4 tertiles in men and women. (A) Estimates of LE with and without NCD (in years) are
plotted against TSH tertiles in men. (B) Estimates of LE with and without NCD (in years) are plotted against TSH tertiles in women. (C) Estimates of LE with
and without NCD (in years) are plotted against FT4 tertiles in men. (D) Estimates of LE with and without NCD (in years) are plotted against FT4 tertiles in
women. NCDs include cardiovascular disease, diabetes mellitus, and cancer. FT4, free thyroxine; LE, life expectancy; NCD, noncommunicable disease; TSH,
thyroid-stimulating hormone.
https://doi.org/10.1371/journal.pmed.1002957.g001
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Discussion
In this large prospective population-based cohort study among middle-aged and older adults,
we found differences in LE with and without NCD within the reference ranges of thyroid func-
tion. Participants with low–normal FT4 levels were expected to live up to 3.7 years longer over-
all, of which up to 1.9 years longer with NCD than those with high–normal FT4 levels.
Participants with high–normal TSH levels were expected to live up to 1.5 years longer overall,
of which up to 1.4 years longer with NCD than those with low–normal TSH levels. No mean-
ingful sex differences throughout the TSH and FT4 tertiles were observed.
Previous studies have suggested that the beneficial effects of high–normal thyroid function
on metabolism can be counterbalanced by detrimental effects on other systems, such as the
cardiovascular system [13,18,19,22]. In this context, our study sheds light on the resultant sys-
tem-specific effects of thyroid function, suggesting that the overall risk of NCD increases in
the high–normal range of FT4 levels. However, the LE estimates not only are attributable to
the risk of developing the diseases but also depend on mortality risk. Similar to previous stud-
ies conducted in middle-aged and older adults, we showed that high–normal thyroid function
is associated with an increased risk of mortality [22,37,38]. This was further translated into a
decreased LE with and without NCD for participants with high–normal thyroid function.
Table 3. LE with and without NCD at age 50 among TSH and FT4 tertiles in men and women.
TSH/FT4
tertiles
Differences in total LE (95% CI) (p-value) Differences in LE free of NCD (95% CI) (p-value) Differences in LE with NCD (95% CI) (p-value)
TSH tertiles†
Men
Tertile 1 Reference Reference Reference
Tertile 2 1.4 (0.5–2.1) (<0.001) 0.6 (−0.3 to 1.4) (0.1) 0.8 (−0.1 to 1.8) (0.09)
Tertile 3 1.5 (0.8–2.3) (<0.001) 0.1 (−0.8 to 1.2) (0.8) 1.4 (0.5–2.3) (0.002)
Women
Tertile 1 Reference Reference Reference
Tertile 2 1.4 (0.6–2.0) (<0.001) 0.7 (−0.2 to 1.6) (0.1) 0.7 (−0.2 to 1.5) (0.1)
Tertile 3 1.5 (0.8–2.2) (<0.001) 0.2 (−0.8 to 1.3) (0.7) 1.3 (0.3–2.1) (0.004)
FT4 tertiles
#
Men
Tertile 1 Reference Reference Reference
Tertile 2 −2.0 (−3.4 to −0.7) (0.003) −1.6 (−2.8 to −0.5) (0.006) −0.4 (−1.6 to 0.9) (0.5)
Tertile 3 −3.7 (−5.1 to −2.2) (<0.001) −1.8 (−3.1 to −0.7) (0.003) −1.9 (−3.4 to −0.3) (0.01)
Women
Tertile 1 Reference Reference Reference
Tertile 2 −1.8 (−3.0 to −0.7) (0.002) −1.7 (−2.9 to −0.6) (0.003) −0.1 (−1.1 to 1.2) (0.8)
Tertile 3 −3.3 (−4.7 to −1.9) (<0.001) −2.0 (−3.4 to −0.7) (0.003) −1.3 (−2.7 to 0.2) (0.07)
NCDs include cardiovascular disease, diabetes mellitus, and cancer. Data are given as years (95% CIs). Multistate life tables were used to calculate LE estimates at the age
of 50 years, using prevalence, incidence rates and hazard ratios for three transitions (healthy to NCD, healthy to death, and NCD to death). The 95% CI estimates were
calculated using Monte Carlo method. The null hypothesis assumes that there are no differences in LE among tertiles of thyroid function measurements. All life
expectancies have been calculated with hazard ratios adjusted for age, cohort, smoking, alcohol intake, education level, marital status, body mass index, systolic blood
pressure, total cholesterol, triglycerides, use of antihypertensive medications, and use of lipid-lowering medications.
†For this analysis, differences in LE are calculated using the first TSH tertile as reference.
#For this analysis, differences in LE are calculated using the first FT4 tertile as reference.
Abbreviations: CI, confidence interval; FT4, free thyroxine; LE, life expectancy; NCD, noncommunicable disease; TSH, thyroid-stimulating hormone
https://doi.org/10.1371/journal.pmed.1002957.t003
Thyroid function and life expectancy with and without disease
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002957 October 25, 2019 10 / 16
More specifically, LE without NCD is the result of two components: risk of incident NCD
(transition 1) and risk of mortality among participants without NCD (transition 2). In our
study, high–normal FT4 levels were associated with a higher risk of incident NCD compared
with low–normal FT4 levels, leading to earlier clinical manifestation of NCD and fewer years
lived without NCD. High–normal FT4 levels were also associated with an increased mortality
risk among participants without NCD, resulting in a further decrease in total LE and LE with-
out NCD. LE with NCD reflects the combined risk of incident NCD (transition 1) and risk of
mortality among participants with NCD (transition 3). We showed that high–normal FT4 lev-
els were associated with a 1.17-times-higher risk of incident NCD compared with low–normal
FT4 levels, meaning an earlier occurrence of NCD across the life span and more years lived
with NCD. However, participants with NCD and high–normal FT4 levels had an even higher
risk of mortality (i.e., 1.56 times higher) than those with low–normal FT4 levels, which explains
the decrease in the number of years lived with NCD.
Another study from our group previously reported that individuals with low–normal thy-
roid function were expected to live more years free of CVD than those with high–normal thy-
roid function [22]. Given the pleiotropic effects of thyroid hormones, the present study
provides a broader perspective by using the multidimensional measure of LE with and without
NCD, taking into account multiple diseases involving a wide array of mechanisms. Our results
indicate that the estimates of LE with and without NCD reflect the combination of all NCDs
and are not driven by one chronic disease alone. In a consistent manner, participants with
low–normal thyroid function were expected to live more years with CVD, diabetes, and can-
cer, respectively, than those with high–normal thyroid function. Also, participants with low–
normal thyroid function were expected to live more years free of CVD, diabetes, and cancer,
respectively, than those with high–normal thyroid function. Together, these differences in the
number of years lived with and without diseases contributed to the total differences in LE
within the reference ranges of thyroid function.
The added values of this population-based cohort study include the investigation of the
association between thyroid function and incident NCD, as well as the evaluation of differ-
ences in LE with and without NCD within the reference ranges of thyroid function. Other
strengths of the study are the large sample size, the prospective design with a long follow-up
period, and the utilization of a multidimensional measure as LE with and without NCD. Par-
ticipants had extensive and detailed information on covariates including exposures, outcomes,
and potential confounders. Events were adjudicated using standardized criteria. Thyroid func-
tion measurements were performed before the occurrence of incident NCD events, and event
assessors were blinded to the thyroid status of participants. The possibility of reverse causation
was taken into account by excluding the events that occurred during the first 2 years of follow-
up. Multiple sensitivity analyses provided consistent findings.
Several limitations should also be considered. We did not have data available on triiodothy-
ronine, the active form of thyroid hormone. Nevertheless, TSH and FT4 represent the most rel-
evant measurements of thyroid function in clinical practice. We also lacked repeated
measurements of thyroid function, even though the normal reference ranges of TSH and FT4
levels are shown to be stable over time [39]. In certain conditions (e.g., pregnancy or critical ill-
nesses), the affinity of thyroid hormones to plasma proteins can be affected by substances
interfering with the FT4 immunoassay. We lacked information on thyroid hormone binding
proteins. However, our population consists of community-dwelling middle-aged and elderly
people, and therefore, the concentrations of thyroid hormone binding proteins are not
expected to have been altered. One can also assume that NCD events may have occurred before
the date of diagnosis. To address this, we excluded the events that occurred within the first two
years of follow-up; and results remained consistent. Furthermore, the exact date of incident
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CKD in our study was uncertain because eGFR measurements were performed only twice. We
could therefore not include CKD in the primary outcome of NCD. However, we used the
repeated measurements of eGFR to determine the slope of eGFR changes over time. Results
remained similar after adding CKD to the definition of NCD. Finally, the possibility of residual
confounding cannot be entirely ruled out because of the observational character of our study.
The Rotterdam Study includes predominantly participants of European descent older than 45
years. Therefore, our findings need to be confirmed in other populations with similar charac-
teristics to our population, as well as in other ethnicities and other age categories.
Our study provides novel insights about the qualitative and quantitative impact of thyroid
function on LE, revealing meaningful differences in LE with and without NCD, within the ref-
erence range of thyroid function. These results add valuable information to the ongoing dis-
cussion on the reference range of thyroid function. Furthermore, these results support a re-
evaluation of the reference ranges of thyroid function in middle-aged and older adults, imply-
ing the possibility of a downward shift of the FT4 current limits. This can, in turn, have further
implications on the diagnosis and treatment of thyroid disease.
Conclusions
In a population of middle-aged and older euthyroid individuals, we found that high–normal
FT4 levels were associated with an increased risk of incident NCD. Furthermore, we found
meaningful differences in LE with and without NCD within the reference ranges of TSH and
FT4 levels. People with low–normal thyroid function were expected to live more years with
and without NCD than those with high–normal thyroid function. These results provide sup-
port for a re-evaluation of the current reference ranges of thyroid function. Future studies in
other populations are warranted to support the generalization of our findings. Additional
research is needed to establish causality and elucidate the underlying mechanisms.
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